This study tests an ointment called diacerein 1% on people with a rare genetic skin condition (EBS) that causes fragile skin and painful blisters. About 80 participants will apply the ointment daily to see if it clears blisters and reduces pain. The trial is double-blind, meaning…
Phase: PHASE2, PHASE3 • Sponsor: TWi Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC